Intrinsiqq
Nuvectis Pharma Inc. logo

Nuvectis Pharma Inc. Insider Trading

NVCT

Compare
Last 12 months

Insiders bought 250K on the open market and sold nothing.

Net open-market
+250K
1 buy · 0 sales
Under a 10b5-1 plan
—
no sales
Insiders who bought / sold
1 / 0
executives and directors
Last open-market buy
Jun 2026
Jun 30, 2026

Get an email when NVCT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Jun 30
    Marlio Charles Mosseri
    Large holder · bought 50,000 at $18.32
    916K
    1.5% of stake
  • Jun 30
    Ron Bentsur
    Chairman & CEO · bought 12,500 at $20.00
    250K
    0.3% of stake
  • Nov 5, 2025
    Ron Bentsur
    Chairman & CEO · bought 5,000 at $5.72
    29K
    0.1% of stake
  • Nov 5, 2025
    Juan Sanchez
    Director · bought 13,000 at $5.79
    75K
    20% of stake
  • Nov 5, 2025
    Matthew L. Kaplan
    Director · bought 11,000 at $5.84
    64K
    9.7% of stake
  • Oct 23, 2025 – Oct 27, 2025
    Marlio Charles Mosseri
    Large holder · bought 154,770 at avg $6.18
    957K
    5.0% of stake
  • Jun 20, 2025
    Marlio Charles Mosseri
    Large holder · bought 5,603 at $7.99
    45K
    0.2% of stake
  • Jun 17, 2025 – Jun 18, 2025
    Marlio Charles Mosseri
    Large holder · bought 33,442 at avg $8.06
    270K
    1.1% of stake
  • May 12, 2025
    Marlio Charles Mosseri
    Large holder · bought 21,167 at $8.11
    172K
    0.7% of stake
  • May 8, 2025 – May 9, 2025
    Marlio Charles Mosseri
    Large holder · bought 27,662 at avg $8.94
    247K
    1.0% of stake
  • Feb 7, 2025
    Marlio Charles Mosseri
    Large holder · bought 240,000 at $5.00
    $1.2M
    9.1% of stake
  • Dec 24, 2024
    Ron Bentsur
    Chairman & CEO · bought 4,500 at $4.65
    21K
    0.1% of stake
  • Dec 13, 2024
    Marlio Charles Mosseri
    Large holder · bought 17,000 at $4.70
    80K
    0.7% of stake
  • Dec 12, 2024 – Dec 13, 2024
    Marlio Charles Mosseri
    Large holder · bought 49,121 at avg $4.66
    229K
    1.9% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NVCT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with NVCT

CompareIntrinsic value
DSGNDesign Therapeutics, Inc.
$9.02-3.22%10
SMMTSummit Therapeutics Inc.
$10.46-1.09%10
MDGLMadrigal Pharmaceuticals, Inc.
$379.10-4.45%10
ARDXArdelyx Inc.
$2.99-2.29%40
AQSTAquestive Therapeutics Inc.
$3.46-6.61%10
PFEPfizer Inc.
$27.40-0.51%30
BMRNBiomarin Pharmaceutical Inc.
$60.41-1.64%45
EBSEmergent BioSolutions Inc.
$5.05-1.94%37

Held by ETFs

NVCT is in 5 US ETFs. The largest of them, with NVCT's weight in each:

Spot a number that looks wrong? Check it in NVCT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing NVCT

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.